Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Bristol-Myers Squibb Co BMY

Healthcare
Bristol-Myers Squibb Company is a biopharmaceutical company engaged in the discovery, development and delivering advanced medicines that help patients prevail over serious diseases. It offers products for various therapeutic classes, which includes oncology, hematology, immunology, cardiovascular and neuroscience. Its pharmaceutical products include chemically synthesized or small molecule... see more

Recent & Breaking News (NYSE:BMY)

Bristol-Myers Squibb Announces New Collaboration to Evaluate Combination Therapy in Colorectal Cancer

Business Wire June 5, 2017

Encouraging Disease Control Rates Observed with Nivolumab Alone or in Combination with Ipilimumab in Refractory or Relapsing Malignant Pleural Mesothelioma Patients: Results from IFCT-1501 MAPS-2 Trial

Business Wire June 5, 2017

Clinical Trial Data for Combination of Epacadostat and Opdivo® (nivolumab) Demonstrate Durable Clinical Responses in Patients with Melanoma and Head and Neck Cancer

Business Wire June 5, 2017

Early, Durable Responses Seen with Sprycel (dasatinib) in First- and Second-Line Treatment of Pediatric Patients with Chronic Myeloid Leukemia in Chronic Phase (CP-CML)

Business Wire June 5, 2017

New Data Evaluating the Safety and Preliminary Relapse-Free Survival of Adjuvant Yervoy (ipilimumab) 3 mg/kg and 10 mg/kg in Resected High-Risk Melanoma Patients Presented at ASCO

Business Wire June 4, 2017

First Presentation of Efficacy Data from CheckMate -204 Evaluating the Combination of Opdivo (nivolumab) and Yervoy (ipilimumab) Demonstrates Anti-tumor Activity in Advanced Melanoma Patients with Brain Metastases

Business Wire June 4, 2017

Bristol-Myers Squibb and QIAGEN Sign Agreement for Use of NGS Technology to Develop Gene Expression Profiles for Immuno-Oncology Therapies

PR Newswire June 3, 2017

Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Demonstrated Promising Activity in Previously Treated Patients with dMMR or MSI-H Metastatic Colorectal Cancer in Phase 2 CheckMate -142 Study

Business Wire June 3, 2017

Anti-LAG-3 (BMS-986016) in Combination with Opdivo (nivolumab) Showed Activity in Patients with Melanoma Who Were Relapsed or Refractory to Anti-PD-1/PD-L1 Therapy

Business Wire June 3, 2017

European Commission Approves Bristol-Myers Squibb’s Opdivo (nivolumab) for Previously Treated Locally Advanced Unresectable or Metastatic Urothelial Carcinoma in Adults After Failure of Prior Platinum-Containing Therapy

Business Wire June 2, 2017

Opdivo (nivolumab) Data in Patients with Advanced Cervical, Vaginal and Vulvar Cancers from Phase 1/2 CheckMate -358 Presented at ASCO

Business Wire June 2, 2017

Bristol-Myers Squibb and Seattle Genetics Expand Clinical Collaboration to Evaluate Combination of Opdivo (Nivolumab) and ADCETRIS® (Brentuximab Vedotin) in Pivotal Phase 3 Clinical Trial in Relapsed Hodgkin Lymphoma

Business Wire June 2, 2017

Drug Makers Stocks on Investors' Radar -- AstraZeneca, Bristol-Myers Squibb, Eli Lilly, and Sanofi

PR Newswire June 1, 2017

22 Stocks Moving In Tuesday's Pre-Market Session

Benzinga.com  May 30, 2017

A Peek Into The Markets: U.S. Stock Futures Down Ahead Of Economic Data

Benzinga.com  May 30, 2017

Advaxis and Bristol-Myers Squibb Announce Clinical Collaboration to Evaluate ADXS-DUAL and Opdivo (nivolumab) in Metastatic Cervical Cancer

Business Wire May 30, 2017

Array BioPharma and Bristol-Myers Squibb Announce Strategic Collaboration

Business Wire May 30, 2017

Bristol-Myers Squibb to Hold Investor Teleconference to Discuss ASCO Highlights

Business Wire May 26, 2017

U.S. Food and Drug Administration Accepts for Priority Review Bristol-Myers Squibb’s Application for Opdivo (nivolumab) in Previously Treated Hepatocellular Carcinoma

Business Wire May 24, 2017

The Most Notable Abstracts Released Ahead Of ASCO 2017

Benzinga.com  May 19, 2017